Zacks Investment Research downgraded shares of Apricus Biosciences, Inc (NASDAQ:APRI) from a buy rating to a sell rating in a research report report published on Tuesday.

According to Zacks, “Apricus Bio operates in the pharmaceutical industry and focuses on research and development in the area of drug delivery. Its proprietary drug delivery technology is called NexACT ┬«. Backed by revenue generating CRO business, Bio-Quant, Inc. and its NexMed USA subsidiary, Apricus Bio has leveraged the flexibility of its proven NexACT┬« drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. The Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. Apricus Bio was formerly known as NexMed, Inc and is headquartered in San Diago, California. “

Separately, HC Wainwright restated a buy rating and issued a $5.00 price objective on shares of Apricus Biosciences in a report on Wednesday, August 30th.

Apricus Biosciences (APRI) traded down $0.04 during mid-day trading on Tuesday, reaching $1.58. 80,880 shares of the company’s stock were exchanged, compared to its average volume of 679,983. Apricus Biosciences has a fifty-two week low of $0.86 and a fifty-two week high of $4.07.

Apricus Biosciences (NASDAQ:APRI) last announced its quarterly earnings data on Thursday, November 2nd. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.15). During the same quarter in the prior year, the firm earned ($0.19) EPS. sell-side analysts expect that Apricus Biosciences will post -0.92 earnings per share for the current year.

WARNING: “Apricus Biosciences, Inc (APRI) Cut to “Sell” at Zacks Investment Research” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/apricus-biosciences-inc-apri-cut-to-sell-at-zacks-investment-research/1694119.html.

About Apricus Biosciences

Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.

Get a free copy of the Zacks research report on Apricus Biosciences (APRI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Apricus Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.